#yourfavoritenews – “Rituximab Plus Velcade as An Effective Therapy for Non-Hodgkin’s Lymphoma Subtypes”




A Phase 2 clinical trial led by Dr. Kristie Blum at Ohio State University Comprehensive Cancer Center revealed encouraging results for the therapeutic combination of rituximab and Velcade in patients with specific subtypes of non-Hodgkin’s lymphoma. Read the article: http://bit.ly/1MAol7i


How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *